Adaptive Biotechnologies (ADPT) Set to Announce Quarterly Earnings on Tuesday

Adaptive Biotechnologies (NASDAQ:ADPT) is scheduled to be announcing its earnings results after the market closes on Tuesday, May 7th. Analysts expect the company to announce earnings of ($0.35) per share for the quarter. Parties interested in participating in the company’s conference call can do so using this link.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Wednesday, February 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.02. Adaptive Biotechnologies had a negative return on equity of 53.65% and a negative net margin of 132.29%. The business had revenue of $45.78 million during the quarter, compared to the consensus estimate of $50.15 million. On average, analysts expect Adaptive Biotechnologies to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Adaptive Biotechnologies Price Performance

Shares of ADPT stock opened at $2.75 on Tuesday. The business has a 50 day simple moving average of $3.21 and a 200 day simple moving average of $3.96. Adaptive Biotechnologies has a 12-month low of $2.28 and a 12-month high of $9.08.

Insider Transactions at Adaptive Biotechnologies

In other Adaptive Biotechnologies news, CEO Chad M. Robins sold 48,673 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $3.43, for a total transaction of $166,948.39. Following the sale, the chief executive officer now owns 2,576,701 shares in the company, valued at approximately $8,838,084.43. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Adaptive Biotechnologies news, CEO Chad M. Robins sold 48,673 shares of Adaptive Biotechnologies stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $3.43, for a total transaction of $166,948.39. Following the transaction, the chief executive officer now directly owns 2,576,701 shares in the company, valued at approximately $8,838,084.43. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Kyle Piskel sold 7,727 shares of Adaptive Biotechnologies stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $3.43, for a total value of $26,503.61. Following the transaction, the insider now owns 123,318 shares in the company, valued at approximately $422,980.74. The disclosure for this sale can be found here. Insiders sold a total of 124,307 shares of company stock valued at $428,090 in the last three months. 5.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. The Goldman Sachs Group decreased their price target on Adaptive Biotechnologies from $11.00 to $5.00 and set a “neutral” rating for the company in a research note on Friday, February 16th. JPMorgan Chase & Co. decreased their target price on shares of Adaptive Biotechnologies from $11.00 to $8.00 and set an “overweight” rating for the company in a research report on Thursday, February 15th. Finally, BTIG Research lowered their target price on shares of Adaptive Biotechnologies from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Thursday, April 4th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $6.80.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.